Wilmerhale on Behalf of Apple INC.
Legal representation / Consumer electronics, software, and online services company.
Based in DC
🤖
AI Overview
With $1.2M in lobbying spend across 12 quarterly filings, Wilmerhale on Behalf of Apple INC is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2023 to 2025.
$1.2M
Total Spend
3
Years Active
1
Firms Hired
2
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $330K |
| 2024 | $440K |
| 2025 | $440K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Health Issues, Trade
- •Issues related to intellectual property. Issues related to public health matters. Issues related to trade.
- •Issues related to intellectual property.
- •Issues related to public health matters.
Related Analysis
Related Investigations
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
Similar Clients
Bayer Corporation (Consolidated Report)
$73.0M total spend
GSK (FKA Glaxosmithkline INC.)
$39.9M total spend
Pharmaceutical Research & Manufacturers of America INC
$9.3M total spend
Siemens Healthineers (FKA Varian Medical Systems, INC.)
$1.9M total spend
Tiber Creek Health Strategies, INC. (on Behalf of Genentech, INC.)
$1.4M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.